Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03084926 | First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors | PHASE1 | COMPLETED | 22 | — | — | Aug 8, 2017 | Dec 13, 2021 | Jan 10, 2022 | 4 | Germany, Switzerland +1 |
Number and grading according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
| Arm | Type | Description |
|---|---|---|
| MP0274 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MP0274 | DRUG | Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons |
INCLUSION CRITERIA 1. Have signed and dated written informed consent prior to performing any study procedure, including screening 2. Are ≥ 18 years old on the day of signing informed consent 3. Have histologically confirmed and documented HER2 positive solid tumor malignancy that is unresectable, l...